Literature DB >> 33132177

Therapeutic effect of metformin on inflammation and apoptosis after spinal cord injury in rats through the Wnt/β-catenin signaling pathway.

Tao Zhang1, Fang Wang2, Kang Li3, Chengwei Lv3, Kai Gao4, Chaoliang Lv5.   

Abstract

OBJECTIVE: To verify the effect of metformin on spinal cord injury (SCI) through Wnt/β-catenin signaling pathway.
BACKGROUND: SCI is a serious traumatic disease of the central nervous system. Wnt/β-catenin signaling pathway plays important roles in SCI. Metformin has been reported to exert neuroprotective effects in the central nervous system. Whether metformin could improve SCI through Wnt/β-catenin signaling pathway remains unclear.
METHODS: Rats were divided into sham group, SCI group, SCI + metformin group, metformin + XAV939 group (XAV939 is an effective inhibitor of the Wnt/β-catenin signaling pathway), and methylprednisolone group. BBB scores were used to detect motor function recovery at different time points (0, 1, 3, 7, 14, 21, and 28 days) in SCI rats. Western blot analysis, immunofluorescence, TUNEL, HE and Nissl staining were used to observe the morphological characteristics of spinal cord tissue and the expression of inflammation and apoptosis in spinal cord neurons.
RESULTS: Metformin(50 mg/kg) promoted motor functional recovery in rats after SCI, increased the expressions of β-catenin and brain derived neurotrophic factor (BDNF), inhibited neuron apoptosis and inflammatory response, and improved the recovery of pathological morphology at the injury site by activating the Wnt/β-catenin signaling pathway.
CONCLUSION: We found a possible mechanism that metformin could reduce inflammation and apoptosis, and promote functional recovery of SCI rats through activating Wnt/β-catenin signaling pathway.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Inflammation; Metformin; Neuroprotection; Spinal cord injury; Wnt/β-catenin signaling pathway

Mesh:

Substances:

Year:  2020        PMID: 33132177     DOI: 10.1016/j.neulet.2020.135440

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  7 in total

Review 1.  Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?

Authors:  Moein Ala; Mahan Ala
Journal:  ACS Pharmacol Transl Sci       Date:  2021-11-01

2.  Development and Evaluation of Novel Metformin Derivative Metformin Threonate for Brain Ischemia Treatment.

Authors:  Gufang Zhang; Shuangshuang Chen; Jia Jia; Chun Liu; Weipeng Wang; Hongjian Zhang; Xuechu Zhen
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

3.  Metformin Protects the Intestinal Barrier by Activating Goblet Cell Maturation and Epithelial Proliferation in Radiation-Induced Enteropathy.

Authors:  Hyosun Jang; Soyeon Kim; Hyewon Kim; Su Hyun Oh; Seo Young Kwak; Hyun-Woo Joo; Seung Bum Lee; Won Il Jang; Sunhoo Park; Sehwan Shim
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

4.  Resveratrol promotes axonal regeneration after spinal cord injury through activating Wnt/β-catenin signaling pathway.

Authors:  Zimin Xiang; Shuai Zhang; Xiaodong Yao; Libin Xu; Jianwei Hu; Chenghui Yin; Jianmei Chen; Hao Xu
Journal:  Aging (Albany NY)       Date:  2021-10-14       Impact factor: 5.682

5.  Effect of Metformin on Locomotor Function Recovery in Rat Spinal Cord Injury Model: A Meta-analysis.

Authors:  Qing Chen; Dong Xie; Qiuju Yao; Lili Yang
Journal:  Oxid Med Cell Longev       Date:  2021-12-13       Impact factor: 6.543

6.  Metformin activates Wnt/β-catenin for the treatment of diabetic osteoporosis.

Authors:  Xiaopeng Huang; Siyun Li; Wenjie Lu; Longjiang Xiong
Journal:  BMC Endocr Disord       Date:  2022-07-22       Impact factor: 3.263

7.  The effect of metformin on ameliorating neurological function deficits and tissue damage in rats following spinal cord injury: A systematic review and network meta-analysis.

Authors:  Long-Yun Zhou; Xu-Qing Chen; Bin-Bin Yu; Meng-Xiao Pan; Lu Fang; Jian Li; Xue-Jun Cui; Min Yao; Xiao Lu
Journal:  Front Neurosci       Date:  2022-08-11       Impact factor: 5.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.